WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion,...

Thermo Fisher Scientific Inc. TMO raised its 2026 outlook after second-quarter earnings and revenues exceeded expectations. The update reflects stronger customer activity, better acquisition performance and improved operating leverage.

Examine the evolution of Thermo Fisher's (TMO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Argent Capital Management LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 35.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,602 shares of the medical research company's...

TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.

Amundi raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 22.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,016,260 shares of the medical research company's stock after buying an additional 369,238...

Jefferies just named five U.S. dividend stocks to its exclusive Global Best Ideas list, and with the S&P 500 stretched to historically expensive valuations, the case for these high-conviction picks has never been more urgent.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbiology laboratories simplify media preparation, improve productivity and enhance sample...

Thermo Fisher Scientific NYSE: TMO reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions.

Thermo Fisher Scientific Inc. (TMO) Q2 2026 Earnings Call Transcript

Thermo Fisher Scientific Inc.  (NYSE:TMO) on Thursday reported second-quarter adjusted earnings of $6.03 per share, beating the street view of $5.71.

Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.03 per share, beating the Zacks Consensus Estimate of $5.71 per share. This compares to earnings of $5.36 per share a year ago.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026. Second Quarter Highlights Second quarter revenue grew 10% to $11.99 billion Second quarter GAAP diluted...

Acumen Wealth Advisors LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 14.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,562 shares of the medical research company's stock...

ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon. The US group was chosen after a competitive tender, with its Patheon pharma services arm taking on...